Please login to the form below

Not currently logged in
Email:
Password:

ankylosing spondylitis

This page shows the latest ankylosing spondylitis news and features for those working in and with pharma, biotech and healthcare.

Novartis gains label boost for Cosentyx

Novartis gains label boost for Cosentyx

Cosentyx has been in the psoriatic arthritis (PsA) market for almost four years now, and has also established itself in plaque psoriasis and ankylosing spondylitis.

Latest news

More from news
Approximately 4 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,

  • An eye towards the biobetter in South Korea An eye towards the biobetter in South Korea

    Emerging area. Marketed in 2007. RA = rheumatoid arthritis; AS = ankylosing spondylitis; CD = Crohn's disease; PA = psoriatic arthritis; PS = psoriasis;  . UC = ulcerative colitis; NHL = non-Hodgkin lymphoma; PCI = percutaneous coronary intervention

  • Gaming tackles back pain

    Built on a strong, simple strategy it used multiple channels to flood the world of men aged 18-40 with symptoms of Ankylosing Spondylitis (AS), a progressive, debilitating condition. ... With a barely pronounceable name, frequent confusion with common

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics